These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12173317)

  • 41. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biochemical markers of bone metabolism in breast cancer.
    Lyubimova NV; Kozharskaya GV; Portnoi SM; Kushlinskii NE
    Bull Exp Biol Med; 2014 Oct; 157(6):769-72. PubMed ID: 25342482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
    Papapoulos SE; Frölich M
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Biochemical bone resorption markers in children with osteosarcoma].
    Ambroszkiewicz J; Gajewska J; Laskowska-Klita T; Woźniak W
    Med Wieku Rozwoj; 2004; 8(2 Pt 1):225-33. PubMed ID: 15738598
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers.
    Garnero P; Delmas PD
    Curr Opin Rheumatol; 2004 Jul; 16(4):428-34. PubMed ID: 15201607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bone markers in the management of metastatic bone disease.
    Lipton A; Costa L; Ali SM; Demers LM
    Cancer Treat Rev; 2001 Jun; 27(3):181-5. PubMed ID: 11417969
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
    Generali D; Berruti A; Tampellini M; Dovio A; Tedoldi S; Bonardi S; Tucci M; Allevi G; Aguggini S; Milani M; Bottini A; Dogliotti L; Angeli A
    Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
    J Urol; 2009 Aug; 182(2):509-15; discussion 515-6. PubMed ID: 19524963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report.
    Shimozuma K; Sonoo H; Fukunaga M; Ichihara K; Aoyama T; Tanaka K
    Jpn J Clin Oncol; 1999 Jan; 29(1):16-22. PubMed ID: 10073146
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Monitoring of bone metastases].
    Pawlega J; Adamczyk A
    Pol Merkur Lekarski; 2000 Mar; 8(45):151-4. PubMed ID: 10870423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.
    Saad F; Lipton A
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S17-23. PubMed ID: 18068486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
    Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of bisphosphonates in patients with metastatic bone disease.
    Berenson JR; Lipton A
    Oncology (Williston Park); 1998 Nov; 12(11):1573-9; discussion 1579-81. PubMed ID: 9834935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure.
    Body JJ; Lipton A; Gralow J; Steger GG; Gao G; Yeh H; Fizazi K
    J Bone Miner Res; 2010 Mar; 25(3):440-6. PubMed ID: 19653815
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer.
    Clemons M; Dranitsaris G; Cole D; Gainford MC
    Oncologist; 2006 Mar; 11(3):227-33. PubMed ID: 16549806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton.
    Papapoulos SE; Hamdy NA; van der Pluijm G
    Cancer; 2000 Jun; 88(12 Suppl):3047-53. PubMed ID: 10898350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Bone targeting agents: bisphosphonates].
    Debiais F
    Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.